Sedana Medical AB

SEDANA

SE0015988373

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 11:29:53 2024-05-02 am EDT			5-day change	1st Jan Change
22.15 ^SEK	-2.21%		+54.68%	-4.36%

Apr. 25	Transcript : Sedana Medical AB, Q1 2024 Earnings Call, Apr 25, 2024
Apr. 25	Sedana Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Sedana Medical AB Provides Earnings Guidance for the Year 2023

October 26, 2023 at 01:00 am EDT

Sedana Medical AB (publ) provided earnings guidance for the year 2023. For the year 2023, the company expects net sales between SEK 145 million and SEK 155 million.

Latest news about Sedana Medical AB

Transcript : Sedana Medical AB, Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
Sedana Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US	Apr. 25	CI
Ola Magnusson and Eva Walde Decline Re-Election as Board Members of Sedana Medical AB	Apr. 22	CI
Transcript : Sedana Medical AB, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Sedana Medical AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Sedana Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Sedana Medical Seeks Pediatric Indication for Sedaconda Medical Device	Dec. 20	MT
Sedana Medical AB Files Submission for Paediatric Indication	Dec. 20	CI
Sedana Medical’s Sedaconda Gains Data Exclusivity, Market Protection in Europe	Nov. 22	MT
Sedana Medical Secures Data Exclusivity and Market Protection for Sedaconda Until 2031	Nov. 22	CI
Sedana Medical AB Announces the Main Results from the Paediatric Isocomfort Study	Nov. 16	CI
Transcript : Sedana Medical AB, Nine Months 2023 Earnings Call, Oct 26, 2023	23-10-26
Sedana Medical AB Provides Earnings Guidance for the Year 2023	23-10-26	CI
Sedana Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Sedana Medical AB Establishes Nomination Committee	23-10-24	CI
Sedana Medical Completes Patient Enrollment for Sevoflurane Trial	23-10-23	MT
Sedana Medical AB Announces Completion of Enrollment	23-10-23	CI
Sedana Medical Wins UK Marketing Approval for Isoflurane Drug; Shares Jump 10%	23-10-10	MT
Sedana Medical AB Announces Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for Sedaconda in United Kingdom	23-10-10	CI
Sedana Medical Secures US Patent for Anesthetic Administration Medical Device	23-09-29	MT
Transcript : Sedana Medical AB, Q2 2023 Earnings Call, Jul 21, 2023	23-07-21
Sedana Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-21	CI
Sedana Medical Slumps 35% as Submission of New Drug Application for Isoflurane Delayed	23-07-12	MT
Sedana Medical AB Informs About Adjusted US Submission Plan Following FDA Interaction	23-07-12	CI

Sedana Medical AB (publ) is a Sweden-based medical technology company. It develops, markets and sales medical devices and conducts drug development for future projects around AnaConDa technology. The AnaConDa technology delivery enables of volatile anaesthetics to invasively ventilated patients. The products portfolio comprises disposable medical devices AnaConDa for administration of volatile anaesthetics, AnaConDa syringes, FlurAbsorb charcoal filters for removing halogenated hydrocarbon anaesthetic gases, different lines and connectors which can be used to connect the FlurAbsorb filter, adaptors, among others. The Companyâs main shareholders are board members, Linc AB and Magiola Consulting AB.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-22 - Annual General Meeting

More about the company